3.08
-0.355(-10.35%)
Currency In USD
| Previous Close | 3.43 |
| Open | 3.46 |
| Day High | 3.46 |
| Day Low | 3.08 |
| 52-Week High | 9.55 |
| 52-Week Low | 2.65 |
| Volume | 781,837 |
| Average Volume | 592,070 |
| Market Cap | 170.16M |
| PE | -1.93 |
| EPS | -1.59 |
| Moving Average 50 Days | 3.22 |
| Moving Average 200 Days | 4.76 |
| Change | -0.36 |
If you invested $1000 in Voyager Therapeutics, Inc. (VYGR) since IPO date, it would be worth $173.24 as of July 16, 2025 at a share price of $3.075. Whereas If you bought $1000 worth of Voyager Therapeutics, Inc. (VYGR) shares 5 years ago, it would be worth $238 as of July 16, 2025 at a share price of $3.075.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
GlobeNewswire Inc.
Jun 10, 2025 11:00 AM GMT
LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Exec
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
GlobeNewswire Inc.
May 15, 2025 11:00 AM GMT
LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demon
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
GlobeNewswire Inc.
Apr 28, 2025 8:30 PM GMT
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg - - Featured data also include anti-amyloid gene therapy for Alzheimer’